Amgen Inc. $AMGN Stock: Simplicity Wealth LLC Grows Stake

Simplicity Wealth LLC raised its stake in Amgen Inc. (NASDAQ:AMGN) by 16.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,305 shares of the medical research company’s stock after buying an additional 1,766 shares during the quarter. Simplicity Wealth LLC’s holdings in Amgen were worth $5,187,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. State Street Corp grew its holdings in Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after purchasing an additional 11,656,755 shares during the period. Bank of America Corp DE acquired a new stake in Amgen in the second quarter worth $1,831,903,000. Wellington Management Group LLP raised its holdings in Amgen by 1,102.7% in the second quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock worth $993,031,000 after purchasing an additional 2,514,254 shares during the period. BlackRock Inc. boosted its position in shares of Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of Amgen by 702.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company’s stock worth $647,126,000 after purchasing an additional 1,344,010 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Nancy Grygiel sold 2,970 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by insiders.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst remains bullish: Piper Sandler maintained its Buy rating and a $457 price target, implying continued confidence in Amgen’s earnings outlook, cash generation and pipeline. Piper Sandler Keeps Buy Rating on Amgen
• Positive Sentiment: Pipeline progress provides a potential catalyst: Amgen’s bemarituzumab study in gastric cancer has reached the Phase 3 finish line. While the report does not provide final efficacy or regulatory results, completion of the trial could eventually support a new oncology growth opportunity. Amgen Bemarituzumab Trial Update
• Neutral Sentiment: Tezspire update offers limited immediate clarity: Amgen reported results for Tezspire, but the available headline does not specify the clinical findings or their commercial implications. Investors will need additional detail to assess the impact on sales expectations. Amgen Reports Tezspire Results
• Negative Sentiment: Patent-cliff and dividend concerns are resurfacing: Coverage questions whether Amgen can protect its dividend when major products lose patent protection. The issue may weigh on the stock because investors are evaluating whether future cash flow can support both shareholder returns and replacement growth. Amgen Dividend and Patent Cliff Risks

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on AMGN shares. Guggenheim decreased their price target on shares of Amgen from $388.00 to $378.00 and set a “neutral” rating for the company in a report on Tuesday, October 13th. Argus raised their price objective on Amgen from $375.00 to $460.00 and gave the stock a “buy” rating in a research note on Wednesday, August 19th. HSBC lowered Amgen from a “buy” rating to a “hold” rating and reduced their target price for the stock from $445.00 to $425.00 in a report on Thursday, September 10th. Weiss Ratings raised Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Finally, Barclays boosted their target price on Amgen from $380.00 to $400.00 and gave the company an “equal weight” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $389.71.

Amgen Price Performance

AMGN stock opened at $439.26 on Friday. The stock has a 50-day moving average price of $417.70 and a two-hundred day moving average price of $377.83. The stock has a market cap of $237.48 billion, a PE ratio of 27.30, a price-to-earnings-growth ratio of 3.22 and a beta of 0.41. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 1 year low of $288.00 and a 1 year high of $450.98.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts forecast that Amgen Inc. will post 22.96 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.